Kodiak Sciences Inc.

Kodiak Sciences Inc. is a biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ophthalmic diseases. It is committed to protecting vision and is designing and developing novel therapies for the treatment of retinal diseases. The company's ABC Platform is at the heart of its portfolio of retina medicines.

In July 2018, Kodiak initiated its first Phase 1a clinical study of KSI-301, an antibody biopolymer conjugate, in patients with diabetic macular edema (DME).

1. 1Next-generation therapies for retinal diseaseskodiak.com
2. 2The ABC Platform - Kodiak Scienceskodiak.com
3. 3Advancing Novel Therapies for Ophthalmic Diseases – Kodiakkodiak.com
4. 4Kodiak Sciences Inc.wikidata.org
5. 5Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stockprnewswire.com
6. 6Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stockprnewswire.com
7. 7Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisorsprnewswire.com
8. 8Kodiak Sciences Appoints Charles Bancroft to Board of Directorsbiospace.com
9. 9Kodiak Sciences Appoints Charles Bancroft to Board of Directorsprnewswire.com
10. 10Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directorsprnewswire.com
11. 11Relmada Therapeutics Announces Pricing of Public Offering of Common Stockprnewswire.com